EFEKTIVITAS PENGGUNAAN OBAT KEMOTERAPI NEOADJUVANT PADA PASIEN KANKER PAYUDARA DI RSUP FATMAWATI JAKARTA

Dea Fauziah; Fajar Amirulah; Dini Permata Sari; Rangki Astiani

doi:10.51225/jps.v9i1.92

Authors

Dea Fauziah Universitas 17 Agustus 1945 Jakarta
Fajar Amirulah Universitas 17 Agustus 1945 Jakarta
Dini Permata Sari Universitas 17 Agustus 1945 Jakarta
Rangki Astiani Universitas 17 Agustus 1945 Jakarta

DOI:

https://doi.org/10.51225/jps.v9i1.92

Keywords:

breast cancer, chemotherapy, effectiveness, neoadjuvant, tumor size, efektivitas, kanker payudara, kemoterapi neoadjuvant, ukuran tumor

Abstract

Kanker payudara merupakan jenis kanker yang paling sering menyerang wanita dan menjadi penyebab utama kematian akibat kanker di Indonesia. Salah satu bentuk terapi utama adalah kemoterapi neoadjuvant yang diberikan sebelum pembedahan untuk mengecilkan ukuran tumor. Penelitian ini bertujuan mengevaluasi efektivitas kemoterapi neoadjuvant pada pasien kanker payudara stadium III di RSUP Fatmawati Jakarta berdasarkan perbedaan ukuran tumor sebelum dan sesudah terapi. Penelitian menggunakan desain deskriptif analitik retrospektif dengan data sekunder dari rekam medis pasien periode Januari 2023–Desember 2024. Sampel berjumlah 60 pasien yang memenuhi kriteria inklusi dan menerima regimen kombinasi CAF serta AC-T. Hasil menunjukkan adanya penurunan ukuran tumor yang signifikan, dari rata-rata 6,24 cm sebelum terapi menjadi 3,91 cm sesudah terapi. Uji Wilcoxon Signed-Rank menghasilkan p<0,05, yang menandakan perbedaan signifikan secara statistik. Disimpulkan bahwa kemoterapi neoadjuvant efektif dalam mengecilkan ukuran tumor pada pasien kanker payudara stadium III. Penelitian ini diharapkan dapat menjadi rujukan dalam pemilihan regimen kemoterapi serta meningkatkan kualitas penanganan kanker payudara di Indonesia

References

Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173

Cho, D. H., Bae, S. Y., You, J. Y., Kim, H. K., Chang, Y. W., Choi, Y. J., Woo, S. U., Son, G. S.,

Lee, J. B., Bae, J. W., & Jung, S. P. (2018). Lymph Node Ratio as an Alternative to pN Staging for Predicting Prognosis After Neoadjuvant Chemotherapy in Breast Cancer. The Kaohsiung Journal of Medical Sciences, 34(6), 341–347. https://doi.org/10.1016/j.kjms.2017.12.015

De Jong, M. (2014). Imaging in oncology: Current evidence and future perspectives. Cancer Imaging, 14(1), 1–10. https://doi.org/10.1186/1470-7330-14-1

Duman, B. B., Afşar, Ç. U., Günaldı, M., Şahin, B., Kara, İ. O., Erkişi, M., & Ercolak, V. (2012). Retrospective Analysis of Neoadjuvant Chemotherapy for Breast Cancer in Turkish Patients. Asian Pacific Journal of Cancer Prevention, 13(8), 4119–4123. https://doi.org/10.7314/apjcp.2012.13.8.4119

Fisher, C. S., Cynthia, X., Gillanders, W. E., Aft, R., Eberlein, T. J., Gao, F., & Margenthaler, J. A. (2011). Neoadjuvant Chemotherapy Is Associated With Improved Survival Compared With Adjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer Only After Complete Pathologic Response. Annals of Surgical Oncology, 19(1), 253–258. https://doi.org/10.1245/s10434-011-1877-y

Freitas, A. J. A. de, Causin, R. L., Varuzza, M. B., Filho, C. M. T. H., Silva, V. D. d., Souza, C. d. P., & Marques, M. M. C. (2021). Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review. Cancers, 13(21), 5477. https://doi.org/10.3390/cancers13215477

Garg, A., & Buchholz, T. A. (2015). Influence of Neoadjuvant Chemotherapy on Radiotherapy for Breast Cancer. Annals of Surgical Oncology, 22(5), 1434–1440. https://doi.org/10.1245/s10434-015-4402-x

Haryani, S. (2021). Evaluasi penggunaan obat kemoterapi pada pasien kanker payudara di RSUP Fatmawati periode Februari 2021. Jurnal Farmasi Klinik, 1(1), 12–18.

Hu, J., Yu, X., Yin, P., Qiu, L., Du, B., & Cai, X. (2021). Intravoxel Incoherent Motion Diffusion- Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy. https://doi.org/10.21203/rs.3.rs-630224/v1

Momenimovahed, Z., & Salehiniya, H. (2019). Epidemiological characteristics and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy, 11, 151–164. https://doi.org/10.2147/BCTT.S176070

Mougalian, S. S., Soulos, P. R., Killelea, B. K., Lannin, D. R., Abu‐Khalaf, M., DiGiovanna, M. P., Sanft, T., Pusztai, L., Gross, C. P., & Chagpar, A. B. (2015). Use of Neoadjuvant Chemotherapy for Patients With Stage I to III Breast Cancer in the United States. Cancer, 121(15), 2544–2552. https://doi.org/10.1002/cncr.29348

Nurrohmah, A., Aprianti, A., & Hartutik, S. (2022). Risk factors of breast cancer. GASTER Journal of Health Science, 20(1), 1–10.

Rahayuwati, L., Rizal, I. A., Pahria, T., Lukman, M., & Juniarti, N. (2020). Pendidikan kesehatan tentang pencegahan penyakit kanker dan menjaga kualitas kesehatan. Media Karya Kesehatan, 3(1), 45–53.

Rezano, A., Pan, C. E., Istiqomah, A. A., & Zada, A. (2018). Association of Ki-67 Expression and Response of Neoadjuvant Chemotherapy in Invasive Breast Cancer Patients in Bandung. International Journal of Integrated Health Sciences, 6(2), 80–83. https://doi.org/10.15850/ijihs.v6n2.1374

Rokom. (2024). Kanker masih membebani dunia. Redaksi Sehat Negeriku.

Wang, Y., Jiao, H., Han, T., Yang, G., Ke, Q., Zhang, Q., & Wang, F. (2024). The Predictive Value of Contrast-Enhanced Ultrasound Combined With Ultrasonic Elastography in Response to Neoadjuvant Chemotherapy in Different Molecular Types of Breast Cancer. https://doi.org/10.21203/rs.3.rs-4213687/v1

Yoshida, A., Hayashi, N., Suzuki, K., Takimoto, M., Nakamura, S., & Yamauchi, H. (2017). Change in HER2 Status After Neoadjuvant Chemotherapy and the Prognostic Impact in Patients With Primary Breast Cancer. Journal of Surgical Oncology, 116(8), 1021–1028. https://doi.org/10.1002/jso.24762

Yu, Y., Wu, S., Xing, H., Han, M., Li, J., & Liu, Y. (2021). Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.675533